The tweet was deleted by the author.
But we saved everything 🙂.
Cullinan Therapeutics has announced its planned milestones for the fourth quarter of 2026 across its immunology and oncology T cell engager portfolio.
The update includes anticipated clinical data releases for CLN-978, velinotamig, and CLN-049, underscoring the company’s ongoing research focus. Further details on these developments are expected closer to the outlined timeline.
View post on X Loading...
Cullinan Therapeutics recently released Phase 3 REZILIENT3 trial data at WCLC26, with further details promised in an upcoming investor webcast, according to a previous announcement. The company has also scheduled a webcast in September to present Phase 3 REZILIENT3 results on zipalertinib plus chemotherapy, as noted in earlier disclosures. These efforts reflect Cullinan’s ongoing focus on advancing its clinical pipeline.